KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Retained Earnings: 2009-2025

Historic Retained Earnings for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $35.0 billion.

  • Regeneron Pharmaceuticals' Retained Earnings rose 13.95% to $35.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 billion, marking a year-over-year increase of 13.95%. This contributed to the annual value of $31.7 billion for FY2024, which is 16.19% up from last year.
  • Regeneron Pharmaceuticals' Retained Earnings amounted to $35.0 billion in Q3 2025, which was up 4.05% from $33.7 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Retained Earnings registered a high of $35.0 billion during Q3 2025, and its lowest value of $12.0 billion during Q1 2021.
  • Moreover, its 3-year median value for Retained Earnings was $29.4 billion (2024), whereas its average is $29.4 billion.
  • Data for Regeneron Pharmaceuticals' Retained Earnings shows a peak YoY spiked of 74.13% (in 2021) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Retained Earnings (Quarterly) stood at $19.0 billion in 2021, then increased by 22.87% to $23.3 billion in 2022, then climbed by 16.96% to $27.3 billion in 2023, then rose by 16.19% to $31.7 billion in 2024, then grew by 13.95% to $35.0 billion in 2025.
  • Its last three reported values are $35.0 billion in Q3 2025, $33.7 billion for Q2 2025, and $32.4 billion during Q1 2025.